Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Asks Court To Keep Purepac’s Neurontin Generic Off The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Brand company’s arguments in support of a preliminary injunction could be bolstered by the fact that, unlike Ivax’ product, Purepac’s gabapentin generic is AB-rated and the Alpharma division has said a launch would not hinge on resolution of patent litigation with Pfizer.

You may also be interested in...



Ivax To Launch Neurontin Generics Early Under Settlement With Alpharma

The company's AB-rated generics of Neurontin capsules can come to market two weeks before Alpharma's 180-day exclusivity period runs out; Ivax' gabapentin tablets will be able to enter the market six weeks early. The settlement ends Ivax' challenge of FDA's patent-based award of generic exclusivity for Pfizer's epilepsy agent.

Ivax To Launch Neurontin Generics Early Under Settlement With Alpharma

The company's AB-rated generics of Neurontin capsules can come to market two weeks before Alpharma's 180-day exclusivity period runs out; Ivax' gabapentin tablets will be able to enter the market six weeks early. The settlement ends Ivax' challenge of FDA's patent-based award of generic exclusivity for Pfizer's epilepsy agent.

Gabapentin Injunction Hearing Continued

A Newark, N.J. federal judge will continue to hear arguments Sept. 27 on Pfizer's request for a preliminary injunction against the launch of Purepac's generic version of Neurontin

Related Content

Topics

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel